Breakthrough in Cancer Diagnostics: Guardant Health Receives FDA Approval for Revolutionary Blood Test

Guardant Health shares experienced a surge following a significant decision by U.S. regulators. The U.S. Food and Drug Administration (FDA) approved the company's groundbreaking blood test for early detection of colorectal cancer. The test, known as Shield, offers a screening option for adults aged 45 and older who have an average risk for this disease. The test received approval at a time when the incidence of colorectal cancer among younger Americans is rising alarmingly. Palo Alto, California-based Guardant Health announced that Shield is now the first blood test approved as a primary screening tool for colorectal cancer. This development could be of great importance, as colorectal cancer is the second leading cause of cancer-related deaths in the U.S.